Evaxion (ADR) (EVAX)
Decodes immune biology with AI to build vaccine candidates and partner programs.
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM.
Evaxion receives Prix Galien UK Award for Best digital health solution
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion announces business update and first quarter 2026 financial results
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on the dual responsibilities of CSO and Chief Operating Officer (COO).
Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026.
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $11.00
Shares of Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior concepts for design of vaccines to combat polio. These concepts, and the underlying research, will be presented at the World Vaccine Congress taking place in Washington D.C. from March 31 to April 2, 2026.
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.75 Average Target Price from Analysts
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 82,140 shares, a growth of 20.9% from the January 29th total of 67,935 shares. Based on an average trading volume of
Evaxion announces business update and full year 2025 financial results
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces full year 2025 financial results.
Evaxion plans to file 2025 annual report later today
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM.
Evaxion expands AI-Immunology™ platform into autoimmune diseases
COPENHAGEN, Denmark, January 13, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will expand the use of its proprietary AI-Immunology™ platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion's 2026 company milestones and provide a company update on January 13, 2026.
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 26.1%
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 125,539 shares, a growth of 26.1% from the November 30th total of 99,564 shares. Based on an average daily volume of 111,335 shares, the short-interest ratio is